Preterm infant fecal microbiota and metabolite profiles are modulated in a probiotic specific manner

In this single-center observational cohort study demonstrates that supplementing an HMO-catabolizing <em>Bifidobacterium</em> probiotic (<em>B. infantis</em> EVC001) results in increased microbial metabolism of milk oligosaccharides and reduced intestinal inflammation relative to a noncatabolizing Lactobacillus probiotic in human milk-fed preterm infants.